ZA200300472B - Process for the preparation of highly pure crystalline (R,S)-cefuroxime axetil. - Google Patents
Process for the preparation of highly pure crystalline (R,S)-cefuroxime axetil. Download PDFInfo
- Publication number
- ZA200300472B ZA200300472B ZA200300472A ZA200300472A ZA200300472B ZA 200300472 B ZA200300472 B ZA 200300472B ZA 200300472 A ZA200300472 A ZA 200300472A ZA 200300472 A ZA200300472 A ZA 200300472A ZA 200300472 B ZA200300472 B ZA 200300472B
- Authority
- ZA
- South Africa
- Prior art keywords
- solvent
- cefuroxime
- group
- amine
- cefuroxime axetil
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 44
- 229960002620 cefuroxime axetil Drugs 0.000 title claims description 32
- 238000002360 preparation method Methods 0.000 title claims description 8
- KEJCWVGMRLCZQQ-YJBYXUATSA-N Cefuroxime axetil Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-YJBYXUATSA-N 0.000 claims description 29
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 27
- 229960001668 cefuroxime Drugs 0.000 claims description 19
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 15
- -1 amine salt Chemical class 0.000 claims description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 10
- 239000012296 anti-solvent Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 239000002798 polar solvent Substances 0.000 claims description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 6
- 238000005886 esterification reaction Methods 0.000 claims description 6
- 238000010626 work up procedure Methods 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 2
- 239000011575 calcium Chemical class 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 2
- 229940043279 diisopropylamine Drugs 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 239000011777 magnesium Chemical class 0.000 claims description 2
- 229910052749 magnesium Chemical class 0.000 claims description 2
- OBYVIBDTOCAXSN-UHFFFAOYSA-N n-butan-2-ylbutan-2-amine Chemical compound CCC(C)NC(C)CC OBYVIBDTOCAXSN-UHFFFAOYSA-N 0.000 claims description 2
- GMTCPFCMAHMEMT-UHFFFAOYSA-N n-decyldecan-1-amine Chemical compound CCCCCCCCCCNCCCCCCCCCC GMTCPFCMAHMEMT-UHFFFAOYSA-N 0.000 claims description 2
- 239000011591 potassium Chemical class 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 238000001953 recrystallisation Methods 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 239000000047 product Substances 0.000 description 9
- 229940093499 ethyl acetate Drugs 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- URDOHUPGIOGTKV-JTBFTWTJSA-M Cefuroxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 URDOHUPGIOGTKV-JTBFTWTJSA-M 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- IKWLIQXIPRUIDU-ZCFIWIBFSA-N (6r)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound OC(=O)C1=CCS[C@@H]2CC(=O)N12 IKWLIQXIPRUIDU-ZCFIWIBFSA-N 0.000 description 1
- IIASCQBFNHWZBE-UHFFFAOYSA-N 1-bromoethyl acetate Chemical compound CC(Br)OC(C)=O IIASCQBFNHWZBE-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229950003588 axetil Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN653DE2000 IN190849B (fr) | 2000-07-17 | 2000-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200300472B true ZA200300472B (en) | 2003-10-16 |
Family
ID=11097069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200300472A ZA200300472B (en) | 2000-07-17 | 2003-01-17 | Process for the preparation of highly pure crystalline (R,S)-cefuroxime axetil. |
Country Status (10)
Country | Link |
---|---|
US (1) | US6833452B2 (fr) |
EP (1) | EP1303523A1 (fr) |
JP (1) | JP2004504325A (fr) |
CN (1) | CN1447812A (fr) |
AU (1) | AU2001270928A1 (fr) |
BR (1) | BR0112598A (fr) |
CA (1) | CA2416695A1 (fr) |
IN (1) | IN190849B (fr) |
WO (1) | WO2002006289A1 (fr) |
ZA (1) | ZA200300472B (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT411996B (de) * | 2000-09-11 | 2004-08-26 | Sandoz Ag | Verfahren zur herstellung von cefuroxim in der form seines n-butylammoniumsalzes |
EP1409492B1 (fr) * | 2001-07-25 | 2008-10-15 | Lupin Limited | Procede ameliore de preparation de cefuroxime axetil |
US6537985B1 (en) * | 2001-11-30 | 2003-03-25 | Phoenix Scientific, Inc. | Antibiotic formulation and a method of making this formulation |
US20030135041A1 (en) | 2002-01-04 | 2003-07-17 | Orchid Chemicals & Pharmaceuticals Limited, India | Synthesis of ceftiofur intermediate |
CN100448879C (zh) | 2004-07-22 | 2009-01-07 | 北京化工大学 | 一种无定型头孢呋辛酯的制备方法 |
DE102005019458A1 (de) | 2005-04-25 | 2006-10-26 | Grünenthal GmbH | Darreichungsform mit verbesserter Freisetzung von Cefuroximaxetil |
ITMI20050871A1 (it) * | 2005-05-13 | 2006-11-14 | Acs Dobfar Spa | Solvato cristallino di cefuroxima acido |
DE102006019619A1 (de) * | 2006-04-25 | 2007-10-31 | Grünenthal GmbH | Kristalline Modifikation von Cefuroximaxetil |
CN103435632B (zh) * | 2013-09-12 | 2016-03-02 | 广东立国制药有限公司 | 一种头孢呋辛酯的制备方法 |
CN105131016A (zh) * | 2015-08-04 | 2015-12-09 | 江苏正大清江制药有限公司 | 一种头孢呋辛酯的制备方法 |
CN106554361B (zh) * | 2016-09-30 | 2018-10-09 | 华北制药河北华民药业有限责任公司 | 一种头孢呋辛酯口服制剂的制备方法 |
CN108586493A (zh) * | 2017-12-18 | 2018-09-28 | 蚌埠丰原医药科技发展有限公司 | 一种结晶型头孢呋辛酯的制备方法 |
CN109705144A (zh) * | 2019-03-05 | 2019-05-03 | 安徽丰原利康制药有限公司 | 一种头孢呋辛酯高得率的生产方法 |
CN109705143A (zh) * | 2019-03-05 | 2019-05-03 | 安徽丰原利康制药有限公司 | 一种头孢呋辛酯提纯的方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1094545A (fr) * | 1976-02-16 | 1981-01-27 | Michael Gregson | Traduction non-disponible |
YU44680B (en) | 1982-07-30 | 1990-12-31 | Glaxo Lab Ltd | Process for obtaining very pure amorphous form of cephuroxim axetile |
GB8320521D0 (en) | 1983-07-29 | 1983-09-01 | Glaxo Group Ltd | Chemical process |
JPH02104590A (ja) * | 1987-06-15 | 1990-04-17 | Toyohiko Kikuchi | 抗生物質の製造方法 |
US5063224A (en) | 1990-07-09 | 1991-11-05 | Eli Lilly And Company | R-cefuroxime axetil |
JP3121903B2 (ja) * | 1992-02-07 | 2001-01-09 | 塩野義製薬株式会社 | デアセチルセファロスポラン酸のカルバモイル化方法 |
IT1277426B1 (it) * | 1995-08-03 | 1997-11-10 | Acs Dobfar Spa | Forma cristallina biodisponibile del cefuroxima axetil |
CN1111537C (zh) * | 1997-05-15 | 2003-06-18 | 第一制糖株式会社 | 高纯晶形头孢呋辛1-乙酰氧乙酯的制备方法 |
ES2171056T3 (es) * | 1998-02-20 | 2002-08-16 | Fako Ilaclari A S | Procedimiento para la fabricacion de cefuroxima axetil cristalina soluble. |
AT411996B (de) * | 2000-09-11 | 2004-08-26 | Sandoz Ag | Verfahren zur herstellung von cefuroxim in der form seines n-butylammoniumsalzes |
EP1409492B1 (fr) * | 2001-07-25 | 2008-10-15 | Lupin Limited | Procede ameliore de preparation de cefuroxime axetil |
-
2000
- 2000-07-17 IN IN653DE2000 patent/IN190849B/en unknown
-
2001
- 2001-07-16 CA CA002416695A patent/CA2416695A1/fr not_active Abandoned
- 2001-07-16 WO PCT/IB2001/001259 patent/WO2002006289A1/fr not_active Application Discontinuation
- 2001-07-16 EP EP01949815A patent/EP1303523A1/fr not_active Withdrawn
- 2001-07-16 US US09/906,256 patent/US6833452B2/en not_active Expired - Fee Related
- 2001-07-16 BR BR0112598-2A patent/BR0112598A/pt not_active Application Discontinuation
- 2001-07-16 JP JP2002512191A patent/JP2004504325A/ja active Pending
- 2001-07-16 AU AU2001270928A patent/AU2001270928A1/en not_active Abandoned
- 2001-07-16 CN CN01814420A patent/CN1447812A/zh active Pending
-
2003
- 2003-01-17 ZA ZA200300472A patent/ZA200300472B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2416695A1 (fr) | 2002-01-24 |
BR0112598A (pt) | 2003-08-12 |
JP2004504325A (ja) | 2004-02-12 |
IN190849B (fr) | 2003-08-23 |
US6833452B2 (en) | 2004-12-21 |
EP1303523A1 (fr) | 2003-04-23 |
WO2002006289A1 (fr) | 2002-01-24 |
AU2001270928A1 (en) | 2002-01-30 |
CN1447812A (zh) | 2003-10-08 |
US20020016456A1 (en) | 2002-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100286417A1 (en) | Crystalline Minocycline Base and Processes for its Preparation | |
ZA200300472B (en) | Process for the preparation of highly pure crystalline (R,S)-cefuroxime axetil. | |
US20050215781A1 (en) | Novel polymorph of cefdinir | |
EP1848724A2 (fr) | Procede de preparation de cefdinir | |
WO2004083217A1 (fr) | Procede ameliore de preparation de cefoxitine | |
US20050080255A1 (en) | Crystalline cefdinir potassium dihydrate | |
WO2004046154A1 (fr) | Nouvel hydrate amorphe d'une cephalosporine | |
NO302122B1 (no) | Rene diastereomere av 3-cefem-4-karboksylsyre-1-(isopropoksykarbonyloksy)etylester, farmasöytiske preparater inneholdende de rene diastereomerene samt anvendelse av disse for fremstilling av medikamenter | |
FI101965B (fi) | Klavulaanihapon 2-amino-2,4,4-trimetyylipentaanisuolan käyttö klavulaa nihapon alkali- tai maa-alkalimetallisuolojen valmistuksessa | |
KR20070088764A (ko) | 세프디니어 칼륨염의 결정형 | |
KR20000070275A (ko) | 정제 방법 | |
US6894162B2 (en) | Intermediates in cephalosporin production | |
WO2005090360A1 (fr) | Nouveau polymorphe de cefdinir | |
US20060149055A1 (en) | Process for the manufacture of cefpodoxime proxetil | |
US20070191602A1 (en) | Crystalline form of cefdinir cesium salt | |
EP1590353B1 (fr) | Procede pour preparer du cefpodoxime proxetil | |
WO2006010978A1 (fr) | Formes polymorphes de cefdinir, et son sel d'imidazole | |
KR960011779B1 (ko) | 세팔로스포린 결정성 수화물의 신규 제조방법 | |
KR960011780B1 (ko) | 세팔로스포린 결정성 수화물의 신규 제조방법 | |
KR100202279B1 (ko) | 세푸록심 에스테르 유도체의 제조방법 | |
KR100327708B1 (ko) | 결정성 세푸록심 악세틸 에스테르의 제조방법 | |
KR100378731B1 (ko) | 결정성 세푸록심 악세틸 에스테르의 제조방법 | |
KR20060073000A (ko) | 세파제돈산의 정제 방법 | |
JPS643182B2 (fr) |